{"schema_version":"secwatch.filing_event.v1","accession":"0000012208-26-000007","form_type":"8-K","ticker":"BIO","cik":"0000012208","company_name":"BIO-RAD LABORATORIES, INC.","filed_at":"2026-02-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.661298+00:00","generated_at":"2026-05-16T02:56:11.573148+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Bio-Rad Q4 GAAP operating loss $118.9M; non-GAAP EPS down to $2.51 from $2.90","bullets":["Q4 GAAP operating loss $118.9M vs income $58.4M YoY; gross margin down 140bps to 49.8%.","Q4 non-GAAP operating income $83.0M (down 10% YoY); non-GAAP EPS $2.51 vs $2.90.","Full-year non-GAAP operating income $311.6M vs $331.3M; EPS $9.92 vs $10.31.","Q4 GAAP net income $720.0M vs $715.8M loss YoY driven by equity investment fair value changes.","CEO cites geopolitical uncertainty and academic funding pressure; Stilla acquisition integrated."],"urls":{"canonical":"https://secwatch.observer/filing/0000012208-26-000007","json":"https://secwatch.observer/filing/0000012208-26-000007.json","markdown":"https://secwatch.observer/filing/0000012208-26-000007.md","text":"https://secwatch.observer/filing/0000012208-26-000007.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/12208/000001220826000007/0000012208-26-000007-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/12208/000001220826000007/bio-20260212.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T02:56:11.573148+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}